---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018269"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:32:41.233520+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari prices $2.5M registered direct offering of ADSs and warrants at $0.80/unit

## Summary
- Issued 3,125,000 ADSs (each representing 2,000 ordinary shares) and Series E/F warrants to purchase up to 3,125,000 ADSs each, all at $0.80 per unit.
- Gross proceeds expected ~$2.5M; closing on or about Oct 16, 2025.
- Warrants exercisable at $0.98 per ADS upon shareholder approval; 5-year term for Series E, 30-month for Series F.
- Net proceeds for working capital, general corporate purposes, and R&D on novel ADC payload.
- Placement agent Ladenburg Thalmann receives 7.2% fee plus warrants for 125,000 ADSs at $1.00.

## SEC filing metadata
- accession: 0001493152-25-018269
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315225018269/0001493152-25-018269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315225018269/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018269
- JSON: https://secwatch.observer/filing/0001493152-25-018269.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.